Sengstake, SarahBergval, Indra LSchuitema, Anja Rde Beer, Jessica LPhelan, Jodyde Zwaan, RinaClark, Taane Gvan Soolingen, DickAnthony, Richard M2018-01-032018-01-032017-07-12Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia. 2017, 17 (1):491 BMC Infect. Dis.1471-23342869780810.1186/s12879-017-2594-3http://hdl.handle.net/10029/621001The ongoing epidemic of multidrug-resistant tuberculosis (MDR-TB) in Georgia highlights the need for more effective control strategies. A new regimen to treat MDR-TB that includes pyrazinamide (PZA) is currently being evaluated and PZA resistance status will largely influence the success of current and future treatment strategies. PZA susceptibility testing was not routinely performed at the National Reference Laboratory (NRL) in Tbilisi between 2010 and September 2015. We here provide a first insight into the prevalence of PZA resistant TB in this region.enArchived with thanks to BMC infectious diseasesAmidohydrolasesAntitubercular AgentsGenotypeGeorgia (Republic)HumansMicrobial Sensitivity TestsMutationMycobacterium tuberculosisPrevalenceProspective StudiesPyrazinamideTuberculosis, Multidrug-ResistantArticleBMC Infect Dis 2017, 17(1):491